If Canadian bureaucrats on the Patent Medicine Prices Review Board (PMPRB) get their way, innovative new drugs and vaccines may not come to Canada in future. The Patent Medicine Prices Review Board (PMPRB) was intended to prevent price gouging by drug companies by dictating the maximum price paid for a drug. However, in its current form it could potentially preclude many life-saving therapies, such as a new vaccine for COVID-19, from reaching Canadians in need. John Adams, president and CEO of CanPKU said, “National pharma care does not deliver therapies to patients. It does not deliver good outcomes to patients. It serves job security for bureaucrats, running process upon process upon process.” Read more here.
(Source: Liz Braun; Toronto Sun; 10/28/20)